Inflammasomes generate signals that cause immune cells to fight infections. Usually this is beneficial, but unwanted inflammation can happen when immune cells become activated without control.
Inflazome is developing inhibitors of the inflammasome, a compelling biological target that regulates our innate immune response, now associated with a wide variety of diseases.
Our small-molecule drugs – drugs that can be taken by mouth – block inflammasomes very precisely. By carefully targeting solely the inflammasome, our therapies have the potential to stop harmful inflammation while allowing beneficial inflammation and minimizing side effects.
Clinical and scientific data suggests that inflammation causes many of our most challenging medical conditions such as Parkinson's, Alzheimers, atherosclerosis and the II diabetes. By blocking the inflammasome we stop inflammation from progressing and inflammation-related diseases may never even develop
Specialties: Inflammasome, Inflammation, Drug Development
TechnologiesPharmaceutical and Drug Discovery
No pipelines published yet
No services posted yet